Once considered cellular junk, non-coding RNAs are emerging as key players in everything from brain development to cancer — ...

Sam Altman shared a story about Paul Conyngham on X, who used ChatGPT and other AI tools to help design a potential mRNA ...

Sarepta (SRPT) stock rises on positive Phase 1/2 siRNA trial data showing muscle delivery, biomarker activity, and safety in ...

Scientists have developed some incredibly advanced ways to actually visualize gene activity in tissues. A sample of tissue ...

An Australian tech entrepreneur has helped create what appears to be a made-to-measure cancer vaccine for his dog, Rosie ...

Scale-up involves increasing pump sizes, reactor volumes, and flow rates—but the process control logic and system ...

Sarepta stock popped Wednesday after the company reported promising results for its gene-silencing tech in two forms of muscular dystrophy.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced a set of strategic efforts designed to accelerate earlier recognition and improve care coordination ...

Beijing has ramped up efforts to increase the inflow of foreign investment with the rollout of 24 policy measures this month, ...

Moderna Inc. has resolved a significant legal overhang that had clouded its future. The biotechnology firm has reached a settlement with Roivant Sciences and Arbutus Biopharma concerning a protracted ...